Access cutting-edge myelodysplastic syndromes treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Access myelodysplastic syndromes specialists in New Haven at no cost
This study follows strict safety protocols and ethical guidelines
All study-related myelodysplastic syndromes treatment provided free
This study (KER-050-D301) is evaluating the efficacy and safety of elritercept (KER-050) versus placebo in adult participants with transfusion-dependent anemia with very low, low, or intermediate risk MDS, or more recently defined as myelodysplastic neoplasms, with or without ring sideroblasts. The study is divided into the Screening Period, Double-blind Treatment Period, Safety Follow-Up Period and Long-term Follow-up Period. Approximately 255 participants will be enrolled, randomized 2:1 to re
Sponsor: Takeda
Check if you qualify for this myelodysplastic syndromes clinical trial in New Haven, CT
If you're searching for myelodysplastic syndromes treatment options in New Haven, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelodysplastic syndromes specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.